These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 28631187)
1. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187 [TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway. Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403 [TBL] [Abstract][Full Text] [Related]
3. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma. Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis. Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin. Li J; Dai X; Zhang H; Zhang W; Sun S; Gao T; Kou Z; Yu H; Guo Y; Du L; Jiang S; Zhang J; Zhou Y Oncotarget; 2015 Oct; 6(30):29196-208. PubMed ID: 26470691 [TBL] [Abstract][Full Text] [Related]
6. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J Front Immunol; 2022; 13():923031. PubMed ID: 35924241 [TBL] [Abstract][Full Text] [Related]
7. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. Zhang Q; Bai X; Chen W; Ma T; Hu Q; Liang C; Xie S; Chen C; Hu L; Xu S; Liang T Carcinogenesis; 2013 May; 34(5):962-73. PubMed ID: 23358852 [TBL] [Abstract][Full Text] [Related]
8. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Ma L; Wang X; Jia T; Wei W; Chua MS; So S Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473 [TBL] [Abstract][Full Text] [Related]
9. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma. Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases. Zhu C; Han H; Li J; Xu L; Liu F; Wu K; Liu X Biomed Res Int; 2019; 2019():9321494. PubMed ID: 31240230 [TBL] [Abstract][Full Text] [Related]
12. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma. Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644 [TBL] [Abstract][Full Text] [Related]
13. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. Drakaki A; Hatziapostolou M; Polytarchou C; Vorvis C; Poultsides GA; Souglakos J; Georgoulias V; Iliopoulos D BMC Cancer; 2015 Jul; 15():542. PubMed ID: 26206264 [TBL] [Abstract][Full Text] [Related]
14. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway. Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804 [TBL] [Abstract][Full Text] [Related]
15. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics. Yang C; Guo L; Du J; Zhang Q; Zhang L Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540686 [TBL] [Abstract][Full Text] [Related]
16. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma. Fan X; Ma X; Cui L; Dang S; Qu J; Zhang J; Wang X; Mao Z Oncotarget; 2016 Dec; 7(49):80404-80414. PubMed ID: 27829235 [TBL] [Abstract][Full Text] [Related]
17. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Chen L; Li M; Li Q; Wang CJ; Xie SQ Mol Cancer; 2013 Dec; 12():157. PubMed ID: 24325363 [TBL] [Abstract][Full Text] [Related]
18. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing β-catenin gene. Wang B; Xunsun ; Liu JY; Yang D; Yang LL; Kong DX; Meng XW Hepatogastroenterology; 2012; 59(114):515-8. PubMed ID: 22024040 [TBL] [Abstract][Full Text] [Related]
19. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma. Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379 [TBL] [Abstract][Full Text] [Related]
20. CDH17 is a downstream effector of HOXA13 in modulating the Wnt/β-catenin signaling pathway in gastric cancer. Qu LP; Zhong YM; Zheng Z; Zhao RX Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1234-1241. PubMed ID: 28387908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]